Table 3 Outcome differences between 1 year and 2 year.

From: An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial

Events

Cordimax (n = 2460)

Xience V (n = 1237)

HR (95% CI)

P value

TLF

28 (1.1%)

21 (1.7%)

0.67 (0.38–1.18)

0.16

All cause death

0 (0%)

2 (0.2%)

—

—

Cardiac death

0 (0%)

0 (0%)

—

—

MI

3 (0.2%)

1 (0.1%)

1.51 (0.16–14.49)

0.72

TLR (clinically driven)

25 (1.0%)

21 (1.7%)

1.01 (1.00–1.07)

0.08

Death or MI

3 (0.2%)

3 (0.2%)

0.50 (0.10–2.49)

0.39

MACE

28 (1.1%)

22 (1.8%)

0.64 (0.37–1.11)

0.11

ST

4 (0.2%)

2 (0.2%)

1.01 (0.18–5.48)

1.00

  1. Values are n (%). *Relative risk (RR) and p values are from the chi-square test. MACE, Major Adverse Cardiovascular Event; MI, Myocardial Infarction; TLF, Target Lesion Failure; TLR, Target Lesion Revascularisation; and ST, Stent Thrombosis.
Back to article page